139 related articles for article (PubMed ID: 34145944)
1. Multiple vertebral fractures after suspension of denosumab. A series of 56 cases.
Sosa-Henríquez M; Torregrosa O; Déniz A; Saavedra P; Ortego N; Turrión A; Pérez Castrillón JL; Díaz-Curiel M; Gómez-Alonso C; Martínez G; Antonio Blázquez J; Olmos-Martínez JM; Etxebarria Í; Caeiro JR; Mora-Peña D
Int J Clin Pract; 2021 Oct; 75(10):e14550. PubMed ID: 34145944
[TBL] [Abstract][Full Text] [Related]
2. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
3. Second rebound-associated vertebral fractures after denosumab discontinuation.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
[TBL] [Abstract][Full Text] [Related]
4. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
[No Abstract] [Full Text] [Related]
5. Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series.
Tripto-Shkolnik L; Liel Y; Yekutiel N; Goldshtein I
Horm Metab Res; 2021 Mar; 53(3):185-190. PubMed ID: 33588445
[TBL] [Abstract][Full Text] [Related]
6. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
[TBL] [Abstract][Full Text] [Related]
7. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
8. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
[No Abstract] [Full Text] [Related]
10. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
11. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature.
Florez H; Ramírez J; Monegal A; Guañabens N; Peris P
Semin Arthritis Rheum; 2019 Oct; 49(2):197-203. PubMed ID: 30826108
[TBL] [Abstract][Full Text] [Related]
13. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
14. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
[TBL] [Abstract][Full Text] [Related]
15. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
16. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
[TBL] [Abstract][Full Text] [Related]
17. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
18. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
19. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
Bandeira F; Torres G; Bandeira E; Duarte MB; Nóbrega AM; Bandeira L
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):163-166. PubMed ID: 30663978
[TBL] [Abstract][Full Text] [Related]
20. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".
Torrente-Segarra V; Roig-Vilaseca D
Rheumatol Int; 2018 Jun; 38(6):1161-1162. PubMed ID: 29546636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]